Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerStatus: open
14-021 - Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial - RTOG 0924
Treatment for Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
Demonstrate that prophylactic, neoadjuvant, androgen-deprivation therapy (NADT) and whole-pelvic radiation therapy (WPRT) will result in improvement in overall survival (OS) of patients with "unfavorable" intermediate-risk or "favorable" high-risk prostate cancer compared to NADT and high-dose prostate (P) and seminal vesicle (SV) radiation therapy (RT) using intensity-modulated RT (IMRT) or external-beam RT (EBRT) with a high-dose rate (HDR) or a permanent prostate (radioactive seed) implant (PPI) boost.
SponsorsThis trial is sponsored by Radiation Therapy Oncology Group.
Interested in Clinical Trial?
Providers Associated With This Trial
- Elesyia D. Outlaw, M.D.Radiation OncologistDirector of Women's Radiotherapy Program; Program Director of Brachytherapy Program; Associate Professor of Interdisciplinary Clinical Oncology
- David R. Clarkson, M.D.Medical Oncologist and HematologistProfessor of Interdisciplinary Clinical Oncology; Fellowship Program Director